TVTX Overview
Upcoming Projects (TVTX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (TVTX)
-
Quarterly Survey: TVTX's Filspari (sparsentan) and CALT's Tarpeyo (budesonide) in treating IgAN April 2024
Tickers: TVTX, CALT
Executed On: Apr 18, 2024 at 04:41 PM EDT -
Quarterly Survey: TVTX's Filspari (sparsentan) and CALT's Tarpeyo (budesonide) in treating IgAN January 2024
Tickers: TVTX, CALT
Executed On: Jan 23, 2024 at 03:55 PM EST -
Delving into the recent phase 3 data from the ALIGN clinical trial of Novartis' atrasentan in patients with IgA Nephropathy.
Tickers: NVS, TVTX, CALT, KDNY
Executed On: Nov 17, 2023 at 09:00 AM EST -
Quarterly Survey: TVTX's Filspari (sparsentan) and CALT's Tarpeyo (budesonide) in treating IgAN October 2023
Tickers: TVTX, CALT
Executed On: Oct 30, 2023 at 05:25 PM EDT -
Evaluating Travere Therapeutics' FILSPARI for the Treatment of IgA Nephropathy: A Comprehensive Analysis
Ticker: TVTX
Executed On: Sep 27, 2023 at 03:30 PM EDT -
Quarterly Survey: IgAN Nephropathy and Filspari (sparsentan) July 2023
Ticker: TVTX
Executed On: Jul 27, 2023 at 01:27 PM EDT -
A Third Opinion: Digging into the IgAN landscape with a focus on Travere's Filspari (sparsentan), Calliditas' Nefecon (Tarpeyo/Kinpeygo), and Chinook's Atrasentan
Tickers: CALT, NVS, TVTX, KDNY
Executed On: Jun 13, 2023 at 04:00 PM EDT -
A Second Opinion: Digging into the IgAN landscape with a focus on Travere's Filspari (sparsentan), Calliditas' Nefecon (Tarpeyo/Kinpeygo), and Chinook's Atrasentan
Tickers: CALT, TVTX, KDNY
Executed On: Jun 06, 2023 at 09:00 AM EDT -
Digging into the IgAN landscape with a focus on Travere's Filspari (sparsentan), Calliditas' Nefecon (Tarpeyo/Kinpeygo), and Chinook's Atrasentan
Tickers: CALT, TVTX, KDNY
Executed On: Jun 01, 2023 at 11:30 AM EDT -
Quarterly Survey: TVTX's Filspari (sparsentan) and CALT's Tarpeyo (budesonide) in treating IgAN
Tickers: TVTX, CALT
Executed On: May 22, 2023 at 04:44 PM EDT -
A Second View: Discussing the focal segmental glomerulosclerosis (FSGS) treatment landscape with a focus on Travere's sparsentan and competing therapies
Ticker: TVTX
Executed On: Apr 18, 2023 at 04:00 PM EDT -
Discussing the focal segmental glomerulosclerosis (FSGS) treatment landscape with a focus on Travere's sparsentan and competing therapies
Ticker: TVTX
Executed On: Apr 05, 2023 at 11:00 AM EDT -
Continuing the Conversation (Part 2): Diving into Travere Therapeutics' Sparsentan in patients with IgA nephropathy ahead of the PDUFA
Ticker: TVTX
Executed On: Feb 03, 2023 at 10:00 AM EST -
Diving into Travere Therapeutics' Sparsentan in patients with IgA nephropathy ahead of the PDUFA
Ticker: TVTX
Executed On: Jan 27, 2023 at 08:30 AM EST -
A Second View - Discussing therapies in development for Homocystinuria including Pegtibatinase from Trevere and Pegtarviliase from Aeglea
Tickers: TVTX, AGLE
Executed On: Oct 04, 2022 at 02:00 PM EDT -
Discussing therapies in development for Homocystinuria including Pegtibatinase from Trevere and Pegtarviliase from Aeglea
Tickers: TVTX, AGLE
Executed On: Sep 22, 2022 at 02:00 PM EDT -
A Discussion of ET and APRIL/BAFF targets in IgAN
Tickers: KDNY, TVTX, VERA
Executed On: Jul 26, 2022 at 10:00 AM EDT
Expired Projects (TVTX)
-
Discussing therapies in development for Homocystinuria including Pegtibatinase from Trevere and Pegtarviliase from Aeglea - 2nd look
Tickers: AGLE, TVTX
Execute By: Sep 30, 2022 -
A Second View: Discussing therapies in development for Homocystinuria including Pegtibatinase from Trevere and Pegtarviliase from Aeglea
Tickers: TVTX, AGLE
Execute By: Sep 30, 2022 -
A look at the PROTECT study data for Sparsentan in patients with IgA nephropathy and the current standard of care
Ticker: TVTX
Execute By: Jun 16, 2022
Upcoming & Overdue Catalysts (TVTX)
-
Travere DUPLEX study for sparsentan in FSGS expected to read out full data in the first half of 2023
Ticker: TVTX
Future Window: Jan 01, 2023 - Jul 01, 2023
Overdue
Occurred Catalysts (TVTX)
-
Travere Therapeutics (TVTX) Announces Topline Interim Results from the Ongoing Phase 3 PROTECT Study of Sparsentan in IgA Nephropathy
Ticker: TVTX
Occurred on: Aug 16, 2021
Strategic Initiatives (TVTX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
